Skip to main content
Have a personal or library account? Click to login
Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies Cover

Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies

Radiology and Oncology
Volume 47 (2013): Issue 4 (December 2013)
By: ,  ,  ,  ,  ,  ,  ,   and    
Open Access
|Oct 2013
References

References

  1. 1. Schmitt M, Magdolen V. Using kallikrein-related peptidases (KLK) as novel cancer biomarkers.2009;222-4.
    Open DOISearch in Google Scholar
  2. 2. GLOBOCAN 2008. Estimated cancer incidence, mortality, prevalence and disability-adjusted life years (DALYs) worldwide in 2008. Available at: http://globocan.iarc.fr/
    Search in Google Scholar
  3. 3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012.2012;10-29.
    Open DOISearch in Google Scholar
  4. 4. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012.2012;220-41.
    Search in Google Scholar
  5. 5. Borgoño CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer.2004;876-90.
    Open DOISearch in Google Scholar
  6. 6. Krenzer S, Peterziel H, Mauch C, Blaber SI, Blaber M, Angel P, et al. Expression and function of the kallikrein-related peptidase 6 in the human melanoma microenvironment.2011;2281-8.
    Open DOISearch in Google Scholar
  7. 7. Pampalakis G, Sotiropoulou G. Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer.2007;22-31.
    Open DOISearch in Google Scholar
  8. 8. Sidiropoulos M, Pampalakis G, Sotiropoulou G, Katsaros D, Diamandis EP. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast ovarian and prostate cancers.2005;324-36.
    Open DOISearch in Google Scholar
  9. 9. Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies.2010;505-11.
    Open DOISearch in Google Scholar
  10. 10. Clements JA. Reflections on the tissue kallikrein and kallikrein-related peptidase family -from mice to men - what have we learnt in the last two decades?2008;1447-54.
    Search in Google Scholar
  11. 11. Clements JA, Willemsen NM, Myers SA, Dong Y. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers.2004;265-312.
    Open DOISearch in Google Scholar
  12. 12. Emami N, Diamandis EP. Utility of kallikrein-related peptidases (KLKs; ascancer biomarkers.2008;1600-7.
    Open DOISearch in Google Scholar
  13. 13. Mavridis K, Scorilas A. Prognostic value and biological role of the kallikreinrelated peptidases in human malignancies.2010;269-5.
    Open DOISearch in Google Scholar
  14. 14. Oikonomopoulou K, Diamandis EP, Hollenberg MD. Kallikrein-related peptidases: proteolysis and signaling in cancer the new frontier.2010;299-310.
    Open DOISearch in Google Scholar
  15. 15. Paliouras M, Diamandis EP. The kallikrein world: an update on the human tissue kallikreins2006;643-562.
    Open DOISearch in Google Scholar
  16. 16. Schmitt M Magdolen V. Using kallikrein-related peptidases (KLK) as novel cancer biomarkers.2009;222-4.
    Open DOISearch in Google Scholar
  17. 17. Yousef GM, Diamandis EP. The human kallikrein gene family: new biomarkers for ovarian cancer.2009;165-87.
    Open DOISearch in Google Scholar
  18. 18. Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer.2005;307-9.
    Open DOISearch in Google Scholar
  19. 19. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.2004;3291-300.
    Open DOISearch in Google Scholar
  20. 20. Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.2003;206s-10s.
    Open DOISearch in Google Scholar
  21. 21. Polterauer S, Vergote I, Concin N, Braicu I, Chekerov R, Mahner S, et al. Prognostic value of residual tumor size in patients with epithelial ovarian cancer international FIGO Stages IIA-IV: analysis of the OVCAD data.2012;380-5.
    Open DOISearch in Google Scholar
  22. 22. Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer.; 2011.
    Open DOISearch in Google Scholar
  23. 23. Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids.2007;1423-32.
    Open DOISearch in Google Scholar
  24. 24. Dorn J, Harbeck N, Kates R, Magdolen V, Grass L, Soosaipillai A, et al. Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma.2006;1121-8.
    Open DOISearch in Google Scholar
  25. 25. Dorn J, Schmitt M, Kates R, Schmalfeldt B, Kiechle M, Scorilas A, et al. Primary tumor levels of human tissue kallikreins impact surgical success and survival in ovarian cancer patients.;1742-8.
    Open DOISearch in Google Scholar
  26. 26. Shan SJ, Scorilas A, Katsaros D, Rigault de la Longrais I, Massobrio M, Diamandis EP. Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols.1879-86.
    Open DOISearch in Google Scholar
  27. 27. Yousef GM, Polymeris ME, Yacoub GM, Scorilas A, Soosaipillai A, Popalis C, et al. Parallel overexpression of seven kallikrein genes in ovarian cancer.2003;2223-7.
    Search in Google Scholar
  28. 28. Zheng Y, Katsaros D, Shan SJ, de la Longrais IR, Porpiglia M, Scorilas A, et al. A multiparametric panel for ovarian cancer diagnosis prognosis response to chemotherapy.2007;6984-92.
    Open DOISearch in Google Scholar
  29. 29. Adib TR, Henderson S, Perrett C, Hewitt D, Bourmpoulia D, Ledermann J, et al. Predicting biomarkers for ovarian cancer using gene-expression microarrays.2004;686-92.
    Open DOISearch in Google Scholar
  30. 30. Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E, et al. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.2006;405-16.
    Open DOISearch in Google Scholar
  31. 31. Dong Y, Kaushal A, Brattsand M, Nicklin J, Clements JA. Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers.2003;1710-20.
    Search in Google Scholar
  32. 32. Dong Y, Kaushal A, Bui L, Chu S, Fuller PJ, Nicklin J, et al. Human kallikrein 4 (KLK4; is highly expressed in serous ovarian carcinomas.2001;2363-71.
    Search in Google Scholar
  33. 33. Gilks CB, Vanderhyden BC, Zhu S, van de Rijn M, Longacre TA. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling.2005;684-94.
    Open DOISearch in Google Scholar
  34. 34. Shvartsman HS, Lue J, Lillie J, Deavers MT, Clifford S, Wolf JK, et al. Overexpression of kallikrein 10 in epithelial ovarian carcinomas.2003;44-50.
    Open DOISearch in Google Scholar
  35. 35. Tanimoto H, Underwood LJ, Shigemasa K, Parmley TH, O’Brien TJ. Increased expression of protease M in ovarian tumors.2001;11-8.
    Open DOISearch in Google Scholar
  36. 36. Tanimoto H, Underwood LJ, Shigemasa K, Yan MS, Clarke J, Parmley TH, et al. The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells.1999;2074-82.
    Open DOISearch in Google Scholar
  37. 37. White NM, Mathews M, Yousef GM, Prizada A, Popadiuk C, Doré JJ. KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma.2009;1107-13.
    Open DOISearch in Google Scholar
  38. 38. Yousef GM, Magklara A, Chang A, Jung K, Katsaros D, Diamandis EP. Cloning of a new member of the human kallikrein gene family KLK14 which is down-regulated in different malignancies.2001;3425-31.
    Search in Google Scholar
  39. 39. Yousef GM, Fracchioli S, Scorilas A, Borgoño CA, Iskander L, Puopolo M, et al. Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer2003;346-55.
    Search in Google Scholar
  40. 40. Yousef GM, Scorilas A, Katsaros D, Fracchioli S, Iskander L, Borgoño C, et al. Prognostic value of the human kallikrein gene 15 expression in ovarian cancer.2003;3119-26.
    Open DOISearch in Google Scholar
  41. 41. Bandiera E, Zanotti L, Bignotti E, Romani C, Tassi R, Todeschini P, et al. Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response.2009;1015-21.
    Open DOISearch in Google Scholar
  42. 42. Borgoño CA, Grass L, Soosaipillai A, Yousef GM, Petraki CD, Howarth DH, et al. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer.2003;9032-41.
    Search in Google Scholar
  43. 43. Diamandis EP, Borgoño CA, Scorilas A, Yousef GM, Harbeck N, Dorn J, et al. Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis.2003;299-309.
    Open DOISearch in Google Scholar
  44. 44. Diamandis EP, Scorilas A, Fracchioli S, van Gramberen M, de Bruijn H, Henrik A, et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma.2003;1035-43.
    Open DOISearch in Google Scholar
  45. 45. Dorn J, Magdolen V, Gkazepis A, Gerte T, Harlozinska A, Sedlaczek P, et al. Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients’ survival.2011;1783-90.
    Open DOISearch in Google Scholar
  46. 46. Kishi T, Grass L, Soosaipillai A, Scorilas A, Harbeck N, Schmalfeldt B, et al. EP. Human kallikrein 8 a novel biomarker for ovarian carcinoma.2003;2771-4.
    Search in Google Scholar
  47. 47. Koh SC, Razvi K, Chan YH, Narasimhan K, Ilancheran A, Low JJ, et al. The Ovarian Cancer Research Consortium of SE Asia. The association with age human tissue kallikreins 6 and 10 and hemostatic markers for survival outcome from epithelial ovarian cancer.2011;183-90.
    Open DOISearch in Google Scholar
  48. 48. Luo LY, Diamandis EP, Look MP, Soosaipillai AP, Foekens JA. Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance.2002;1790-6.
    Open DOISearch in Google Scholar
  49. 49. Oikonomopoulou K, Li L, Zheng Y, Simon I, Wolfert RL, Valik D, et al. Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel.2008;1103-13.
    Open DOISearch in Google Scholar
  50. 50. zur Hausen H. Papillomaviruses - to vaccination and beyond.(Mosc) 2008;498-503.
    Open DOISearch in Google Scholar
  51. 51. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.1999;1144-53.
    Open DOISearch in Google Scholar
  52. 52. Micke O, Bruns F, Schäfer U, Prott FJ, Willich N. The impact of squamous cell carcinoma (SCC) antigen in patients with advanced cancer of uterine cervix treated with (chemo)-radiotherapy.2005;1663-6.
    Search in Google Scholar
  53. 53. Tian X, Shigemasa K, Hirata E, Gu L, Uebaba Y, Nagai N, et al. Expression of human kallikrein 7 (hK7/SCCE) and its inhibitor antileukoprotease (ALP/ SLPI) in uterine endocervical glands and in cervical adenocarcinomas.2004;1001-6.
    Open DOISearch in Google Scholar
  54. 54. Petraki CD, Papanastasiou PA, Karavana VN, Diamandis EP. Cellular distribution of human tissue kallikreins: immunohistochemical localization.2006;653-63.
    Open DOISearch in Google Scholar
  55. 55. Santin AD, Cane S, Bellone S, Bignotti E, Palmieri M, de las Casas LE, et al. The serine protease stratum corneum chymotryptic enzyme (kallikrein 7) is highly overexpressed in squamous cervical cancer cells.2004;283-8.
    Open DOISearch in Google Scholar
  56. 56. Santin AD, Cane’ S, Bellone S, Bignotti E, Palmieri M, De Las Casas LE, et al. The novel serine protease tumor-associated differentially expressed gene-14 (KLK8/neuropsin/ovasin) is highly overexpressed in cervical cancer.2004;60-6.
    Search in Google Scholar
  57. 57. Termini L, Maciag PC, Soares FA, Nonogaki S, Pereira SM, Alves VA, et al. Analysis of human kallikrein 7 expression as a potential biomarker in cervical neoplasia.2010;485-90.
    Open DOISearch in Google Scholar
  58. 58. Bovicelli A, D’Andrilli G, Giordano A, de Iaco P. Conservative treatment of early endometrial cancer.2012;1154-8.
    Open DOISearch in Google Scholar
  59. 59. Stuckey A. Breast cancer: epidemiology and risk factors.2011;96-102.
    Open DOISearch in Google Scholar
  60. 60. Marić P, Ozretić P, Levanat S, Oresković S, Antunac K, Beketić-Oresković L. Tumor markers in breast cancer--evaluation of their clinical usefulness.2011;241-7.
    Search in Google Scholar
  61. 61. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value?2006;345-51.
    Search in Google Scholar
  62. 62. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.2007;5287-312.
    Open DOISearch in Google Scholar
  63. 63. Naidoo S, Raidoo DM. Angiogenesis in cervical cancer is mediated by HeLa metabolites through endothelial cell tissue kallikrein.2009;285-93.
    Open DOISearch in Google Scholar
  64. 64. Sher YP, Chou CC, Chou RH, Wu HM, Wayne Chang WS, Chen CH, et al. Human kallikrein 8 protease confers a favorable clinical outcome in nonsmall cell lung cancer by suppressing tumor cell invasiveness.2006;11763-70.
    Open DOISearch in Google Scholar
  65. 65. Tham SM, Ng KH, Pook SH, Esuvaranathan K, Mahendran R. Tumor and microen- vironment modification during progression of murine orthotopic bladder cancer.2011;865684
    Open DOISearch in Google Scholar
  66. 66. Mangé A, Desmetz C, Berthes ML, Maudelonde T, Solassol J. Specific increase of human kallikrein 4 mRNA and protein levels in breast cancer stromal cells2008;107-12.
    Search in Google Scholar
  67. 67. Monne M, Croce CM, Yu H, Diamandis EP. Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors.1994;6344-7.
    Search in Google Scholar
  68. 68. Yu H, Levesque MA, Clark GM, Diamandis EP. Prognostic value of prostatespecific antigen for women with breast cancer: a large United States cohort study.1998;1489-97.
    Search in Google Scholar
  69. 69. Petraki CD, Papanastasiou PA, Karavana VN, Diamandis EP. Cellular distribution of human tissue kallikreins: immunohistochemical localization.2006;653-63.
    Open DOISearch in Google Scholar
  70. 70. Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidases in prostate breast and ovarian cancers: from pathobiology to clinical relevance.2012;301-17.
    Open DOISearch in Google Scholar
  71. 71. Yousef GM, Yacoub GM, Polymeris ME, Popalis C, Soosaipillai A, Diamandis EP. Kallikrein gene downregulation in breast cancer.2004;167-72.
    Open DOISearch in Google Scholar
  72. 72. Obiezu CV, Diamandis EP. Human tissue kallikrein gene family: applications in cancer.2005;1-22.
    Open DOISearch in Google Scholar
  73. 73. Foekens JA, Diamandis EP, Yu H, Look MP, Meijer-van Gelder ME, van Putten WL, Klijn J. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.1999;888-94.
    Open DOISearch in Google Scholar
  74. 74. Diamandis EP, Helle SI, Yu H, Melegos DN, Lundgren S, Lonning PE. Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma.1999;891-8.
    Open DOISearch in Google Scholar
  75. 75. Lee JY, Park AK, Lee KM, Park SK, Han S, Han W, et al. Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women.2009;1528-31.
    Open DOISearch in Google Scholar
  76. 76. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists.2006;57-9.
    Open DOISearch in Google Scholar
  77. 77. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, et al. Exone sequencing identifies recurrent SPOP FOXA1 and MED12 mutations in prostate cancer.2012;685-9.
    Open DOISearch in Google Scholar
  78. 78. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, et al. The genomic complexity of primary human prostate cancer.2011;214-20.
    Open DOISearch in Google Scholar
  79. 79. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers.2010;899-905.
    Open DOISearch in Google Scholar
  80. 80. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, et al. The mutational landscape of lethal castration-resistant prostate cancer.2012;239-43.
    Open DOISearch in Google Scholar
  81. 81. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer.2010;11-22.
    Open DOISearch in Google Scholar
  82. 82. Fendler A, Jung M, Stephan C, Honey RJ, Stewart RJ, Pace KT, et al. miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression.2011;1183-92.
    Search in Google Scholar
  83. 83. Nam RK, Diamandis EP, Toi A, Trachtenberg J, Magklara A, Scorilas A, et al. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen.2000;1036-42.
    Open DOISearch in Google Scholar
  84. 84. Mavridis K, Avgeris M, Koutalellis G, Stravodimos K, Scorilas A. Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia.2010;693-9.
    Open DOISearch in Google Scholar
  85. 85. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure function and association to disease.2001;184-204.
    Search in Google Scholar
  86. 86. Lawrence MG, Lai J, Clements JA. Kallikreins on steroids: structure unction and hormonal regulation of prostate-specific antigen and the extended kallikrein locus.2010;407-46.
    Open DOISearch in Google Scholar
  87. 87. Lai J, Myers SA, Lawrence MG, Odorico DM, Clements JA. Direct progesterone receptor and indirect androgen receptor interactions with the kallikrein-related peptidase 4 gene promoter in breast and prostate cancer.2009;129-41.
    Open DOISearch in Google Scholar
  88. 88. Olkhov-Mitsel E, van der Kwast T, Kron KJ, Ozcelik H, Briollais L, Massey C, et al. Quantitative DNA methylation analysis of genes coding for kallikreinrelated peptidases 6 and 10 as biomarkers for prostate cancer.2012;1037-45.
    Open DOISearch in Google Scholar
  89. 89. Pampalakis G, Diamandis EP, Sotiropoulou G. The epigenetic basis for the aberrant expression of kallikreins in human cancers.2006;795-9.
    Open DOISearch in Google Scholar
  90. 90. Pasic MD, Olkhov E, Bapat B, Yousef GM. Epigenetic regulation of kallikreinrelated peptidases: there is a whole new world out there.2012;319-30.
    Open DOISearch in Google Scholar
  91. 91. White NM, Youssef YM, Fendler A, Stephan C, Jung K, Yousef GM. The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer.2012;379-89.
    Open DOISearch in Google Scholar
  92. 92. Viatori M. Testicular cancer.2012;180-9.
    Open DOISearch in Google Scholar
  93. 93. Okamoto K. Epigenetics: a way to understand the origin and biology of testicular germ cell tumors.2012;504-11.
    Open DOISearch in Google Scholar
  94. 94. Barlow LJ, Badalato GM, McKiernan JM. Serum tumor markers in the evaluation of male germ cell tumors.2010;610-7.
    Open DOISearch in Google Scholar
  95. 95. Salem M, Gilligan T. Serum tumor markers and their utilization in the management of germ-cell tumors in adult males.2011;1-4.
    Open DOISearch in Google Scholar
  96. 96. Emerson RE, Ulbright TM. Intratubular germ cell neoplasia of the testis and its associated cancers: the use of novel biomarkers.2010;344-55.
    Search in Google Scholar
  97. 97. Favilla V, Cimino S, Madonia M, Morgia G. New advances in clinical biomarkers in testis cancer.2010;456-77.
    Search in Google Scholar
  98. 98. Chieffi P. New prognostic markers and potential therapeutic targets in human testicular germ cell tumors.2011;5033-40.
    Open DOISearch in Google Scholar
  99. 99. Luo LY, Yousef G, Diamandis EP. Human tissue kallikreins and testicular cancer.2003;225-32.
    Open DOISearch in Google Scholar
  100. 100. Yousef GM, Obiezu CV, Jung K, Stephan C, Scorilas A, Diamandis EP. Differential expression of kallikrein gene 5 in cancerous and normal testicular tissues.2002;714-8.
    Open DOISearch in Google Scholar
  101. 101. Luo LY, Rajpert-de Meyts ER, Jung K, Diamandis EP. Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue.2001;220-4.
    Open DOISearch in Google Scholar
  102. 102. Chang A, Yousef GM, Jung K, Rajpert-de Meyts E, Diamandis EP. Identification and molecular characterization of five novel kallikrein gene 13 (KLK13; KLK-L4; splice variants: differential expression in the human testis and testicular cancer.2001;3147-52.
    Search in Google Scholar
  103. 103. Yousef GM, Magklara A, Chang A, Jung K, Katsaros D, Diamandis EP. Cloning of a new member of the human kallikrein gene family KLK14 which is down-regulated in different malignancies.2001;3425-31.
    Search in Google Scholar
  104. 104. Arsanious A, Bjarnason GA, Yousef GM. From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma.2009;20
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/raon-2013-0053 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 319 - 329
Published on: Oct 8, 2013
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
cancer,
proteases,
endometrium,
ovary,
uterus,
prostate,
testis,
cervix,
breast
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2013 Manfred Schmitt, Viktor Magdolen, Feng Yang, Marion Kiechle, Jane Bayani, George M. Yousef, Andreas Scorilas, Eleftherios P. Diamandis, Julia Dorn, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.

Volume 47 (2013): Issue 4 (December 2013)
Previous article
Next article